Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 255Breast Neoplasms 218Lung Neoplasms 206Glioblastoma 202Head and Neck Neoplasms 193Prostatic Neoplasms 179Squamous Cell Carcinoma of Head and Neck 171Lymphoma 152Rectal Neoplasms 138Esophageal Neoplasms 125Central Nervous System Neoplasms 122Leukemia 111Brain Neoplasms 106Pancreatic Neoplasms 96Precursor Cell Lymphoblastic Leukemia-Lymphoma 93Gliosarcoma 87Esophageal Squamous Cell Carcinoma 84Sarcoma 82Uterine Cervical Neoplasms 81Lymphoma, Follicular 81Neoplasms 80Lymphoma, Large B-Cell, Diffuse 80Lymphoma, Non-Hodgkin 75Hodgkin Disease 74Glioma 68Burkitt Lymphoma 67Colorectal Neoplasms 66Leukemia, Lymphocytic, Chronic, B-Cell 63Astrocytoma 63Neoplasm Metastasis 60

Interventions

irinotecan sucrosofate 1camrelizumab 1Radiotherapy 1Capecitabine 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Rectal Cancer Patients × Radiotherapy × Clear all
NCT07291401 2025-12-18

Radiotherapy Plus CAPOX, and Iparomlimab and Tuvonralimab (QL1706) as Neoadjuvant Therapy for LARC

Zhongnan Hospital

Phase 2 Not yet recruiting
108 enrolled
Gastrointestinal

Rectal Cancer Patients

Data powered by HemOnc (CC BY 4.0) Colophon âš¡